Ergoteles’s Neuropace NPCE Stock Holding History

Ergoteles’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-31,027	Closed	-$116K	–	1744
2022 Q3	$116K	Sell	31,027 -3,773	-11%	-$18.2K	﹤0.01%	1339
2022 Q2	$172K	Buy	+34,800	New	+$230K	0.01%	1381

Other funds holding NPCE

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's NPCE Position: Q4 2022 in Review

Ergoteles sold out of Neuropace (NPCE) in Q4 2022, closing a stake of 31,027 shares — an estimated $116K sold.

Ergoteles first reported a position in NPCE in Q2 2022 and held it in 2 quarters. The position peaked at $172K in Q2 2022. 24 funds tracked by Wall St. Rank hold NPCE as of Q4 2022.

Ergoteles reported no remaining Neuropace position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 31,027 Neuropace shares in Q4 2022, an estimated $116K.
Ergoteles first reported a position in Neuropace in Q2 2022 and held it in 2 quarters.
Ergoteles's Neuropace position peaked at $172K in Q2 2022.
24 funds tracked by Wall St. Rank held Neuropace as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.